This application is a for 5-year renewal of the program project, Healthy Aging and Senile Dementia (HASD), now in its 14th year. In this renewal there is a continued focus on the clinical, psychometric, and neuropathologic correlates of DAT in comparison with healthy aging. Five interactive and supportive Cores are proposed: Core A: Clinical recruits, enrolls, and clinically assesses subjects annually to supply all projects; Core B: Psychometrics provides longitudinal cognitive assessments of subjects; Core C: Neuropathology performs postmortem examinations for clinicopathological correlation for all studies and provides appropriate tissue and data to Projects 2 and 4; Core D: Biostatistics oversees data management and provides statistical input to all Cores and projects; and Core E: Administration provides administrative support to all components and assures progress in accomplishing program project goals. Three current projects continue. Project 1 (""""""""Intellect and Alzheimer changes in the very old"""""""") examines clinical, psychometric, and neuropathologic differences and overlap in nondemented and demented subjects greater than or equal to 85. Project 2 (""""""""Mapping of neuropathology in healthy aging and dementia"""""""") studies preclinical stages of Alzheimer's disease (AD) in comparison with healthy brain aging and mild DAT. Project 3 (""""""""Frontal control systems and memory in aging and DAT"""""""") explores the contributions of medial temporal and frontal systems to cognitive performance in aging and DAT. A new study, Project 4 (""""""""Imaging neuronal loss with MRI/MRS in DAT and controls"""""""") evaluates the ability of sensitive neuroimaging measures to discriminate aging and very mild DAT. Together, these projects and their supporting cores will define very mild DAT in comparison with healthy brain aging and address the critical problem of whether aging and AD are continuous or discrete processes.
| Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558 |
| Joseph-Mathurin, Nelly; Su, Yi; Blazey, Tyler M et al. (2018) Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease. Alzheimers Dement (Amst) 10:669-677 |
| Del-Aguila, Jorge L; Fernández, Maria Victoria; Schindler, Suzanne et al. (2018) Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of Memory Decline. J Alzheimers Dis 62:745-756 |
| Oxtoby, Neil P; Young, Alexandra L; Cash, David M et al. (2018) Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain 141:1529-1544 |
| Mishra, Shruti; Blazey, Tyler M; Holtzman, David M et al. (2018) Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ?4 genotype. Brain 141:1828-1839 |
| Bonham, Luke W; Karch, Celeste M; Fan, Chun C et al. (2018) CXCR4 involvement in neurodegenerative diseases. Transl Psychiatry 8:73 |
| Schindler, Suzanne E; Gray, Julia D; Gordon, Brian A et al. (2018) Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 14:1460-1469 |
| Wildburger, Norelle C; Gyngard, Frank; Guillermier, Christelle et al. (2018) Amyloid-? Plaques in Clinical Alzheimer's Disease Brain Incorporate Stable Isotope Tracer In Vivo and Exhibit Nanoscale Heterogeneity. Front Neurol 9:169 |
| Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17 |
| Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221 |
Showing the most recent 10 out of 911 publications
